2-(3-ethoxy-5-ethylsulfanyl-4-methoxyphenyl)ethanamine | 90132-51-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-ethoxy-5-ethylsulfanyl-4-methoxyphenyl)ethanamine
• 英文别名: 2-(3-Ethoxy-5-(ethylthio)-4-methoxyphenyl)ethanamine
• CAS: 90132-51-7
• 化学式: C₁₃H₂₁NO₂S
• 分子量: 255.381
• InChiKey: BTJFGKUKBHSKHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-溴-5-乙氧基-4-羟基苯甲醛 在 盐酸 、 sodium hydroxide 、 正丁基锂 、 2-甲基-2-丁烯 、 dimethyl sulfide borane 、 碘 、 potassium carbonate 、 一水合肼 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 7.75h， 生成 2-(3-ethoxy-5-ethylsulfanyl-4-methoxyphenyl)ethanamine
  参考文献：
  名称：

  拟精神病药物的硫类似物。3.甲斯卡灵及其单硫代类似物的乙基同系物。

  摘要：

  合成了麦斯卡林单，二和三乙氧基同系物的所有可能的单硫代类似物，并在人体中进行了药理学评估。在乙胺链对位的环位置进行的修饰，无论是被硫原子，更长的烷基链，还是两者都被修饰，都会导致中枢神经系统活性高的化合物。还合成了4-正丙氧基和4-正丁氧基同系物及其相应的4-硫代类似物，并进行了药理学评价。丙基同系物保留了高效力，但是丁基（具有或不具有硫原子）导致活性降低。间乙基或间硫代类似物保留一些中心作用，但是二乙氧基，尤其是三乙氧基同系物作为拟精神病药物相对无效。

  DOI：

  10.1021/jm00373a013

文献信息

• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
  申请人：STAMETS Paul Edward

  公开号：US20210069170A1

  公开（公告）日：2021-03-11

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum ) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica , or Cannabis ruderalis , optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
• COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
  申请人：CAAMTECH, INC.

  公开号：US20210346346A1

  公开（公告）日：2021-11-11

  Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
• [EN] TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH<br/>[FR] COMPOSITIONS DE TRYPTAMINES DESTINÉES À AMÉLIORER L'EXCROISSANCE DES NEURITES
  申请人：STAMETS PAUL EDWARD

  公开号：WO2021101926A1

  公开（公告）日：2021-05-27

  Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.
• [EN] COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE PATHOLOGIES NEUROLOGIQUES
  申请人：[en]WESANA HEALTH INC.

  公开号：WO2022115796A1

  公开（公告）日：2022-06-02

  As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating neurological conditions (e.g., traumatic brain injury or TBI), or symptoms thereof (e.g., anxiety or depression), with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., TBI), or symptoms thereof (e.g., anxiety or depression).